<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35608787</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-6776</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biotechnology letters</Title>
          <ISOAbbreviation>Biotechnol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10529-022-03259-6</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">In the wake of SARS-CoV-2's global spread, human activities from health to social life to education have been affected. Favipiravir and Molnupiravir exhibited novel hexokinase inhibition and we discuss advantages of this property in their COVID-19 inhibition potential.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This paper describes molecular docking data of human hexokinase II with Favipiravir, Cyan 20, Remdesivir, 2DG, and Molnupiravir along with hexokinase inhibition assays.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Favipiravir, an antiviral drug previously cleared for treating the flu and ebola, has shown some promise in early trials to treat COVID-19. We observed potent human hexokinase inhibiting potential of Favipiravir (50%) as against 4% and merely 0.3% hexokinase inhibition with Molnupiravir and 2 Deoxy D glucose at 0.1 mM concentration supported by molecular docking studies.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Favipiravir could continue to be part of the COVID-19 treatment regimen due to its resistance to host esterases, hexokinase inhibition potential and proven safety through human trials.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kulkarni</LastName>
            <ForeName>Prajakta</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Herbal Division, Sava Healthcare Limited, Research Center, Block D1, Plot No. 17/6, MIDC, Chinchwad, Pune, 411019, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Padmanabhan</LastName>
            <ForeName>Sriram</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-8049-3703</Identifier>
            <AffiliationInfo>
              <Affiliation>Herbal Division, Sava Healthcare Limited, Research Center, Block D1, Plot No. 17/6, MIDC, Chinchwad, Pune, 411019, India. sriram.p@savaglobal.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biotechnol Lett</MedlineTA>
        <NlmUniqueID>8008051</NlmUniqueID>
        <ISSNLinking>0141-5492</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">2 Deoxy D glucose</Keyword>
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Favipiravir</Keyword>
        <Keyword MajorTopicYN="N">Hexokinase</Keyword>
        <Keyword MajorTopicYN="N">Molecular docking</Keyword>
        <Keyword MajorTopicYN="N">Molnupiravir</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>11</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35608787</ArticleId>
        <ArticleId IdType="doi">10.1007/s10529-022-03259-6</ArticleId>
        <ArticleId IdType="pii">10.1007/s10529-022-03259-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abdelnabi R, Foo CS, Kaptein SJF et al (2021) The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of efficacy 1 in a SARS-CoV2 hamster infection model through an increased frequency of mutations in the viral 2 genome. EBioMedicine 72:103595</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34571361</ArticleId>
            <ArticleId IdType="pmc">8461366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abuga K, Nyamweya N (2021) Alcohol-based hand sanitizers in COVID-19 prevention: a multidimensional perspective. Pharmacy 9:64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33808754</ArticleId>
            <ArticleId IdType="pmc">8006002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agrawal U, Raju R, Udwadia ZF (2020) Favipiravir: a new and emerging antiviral option in COVID-19. Med J Armed Forces India 76:370–376</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32895599</ArticleId>
            <ArticleId IdType="pmc">7467067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ajaz S, McPhail MJ, Singh KK et al (2021) Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19. Am J Physiol Cell Physiol 320:C57–C65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33151090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Masoudi NA, Elias RS, Saeed B (2020) Molecular docking studies of some antiviral and antimalarial drugs via bindings to 3CL-protease and polymerase enzymes of the novel coronavirus (SARSCoV-2). Biointerface Res Appl Chem 10:6444–6459</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Ziaydi AG, Al-Shammari AM, Hamzah MI et al (2020) Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells. Cancer Cell Int 20:420</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32874134</ArticleId>
            <ArticleId IdType="pmc">7456035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahar FG, Ohura K, Ogihara T et al (2012) Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci 101:3979–3988</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22833171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatt AN, Kumar A, Rai Y et al (2022) Glycolytic inhibitor 2-Deoxy-D-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions. Life Sci 295:120411</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35181310</ArticleId>
            <ArticleId IdType="pmc">8847085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai Q, Yang M, Liu D et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 6:1192–1198</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32346491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Zhang Y, Huang J, Yin P et al (2020) Favipiravir versus arbidol for COVID-19: a randomized clinical trial. Front Pharmacol 12:683296</Citation>
        </Reference>
        <Reference>
          <Citation>Chien M, Anderson TK, Jockusch S et al (2020) Nucleotide analogues as Inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J Proteome Res 19(11):4690–4697</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32692185</ArticleId>
            <ArticleId IdType="pmc">7640960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Courteau L, Crasto J, Hassanzadeh G et al (2015) Hexokinase 2 controls cellular stress response through localization of an RNA-binding protein. Cell Death Dis 6:e1837</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26247723</ArticleId>
            <ArticleId IdType="pmc">4558502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darazam IA, Shokouhi S, Pourhoseingholi MA et al (2021) Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Sci Rep 11:8059</Citation>
        </Reference>
        <Reference>
          <Citation>Doi K, Ikeda M, Hayase N et al (2020) Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with COVID-19: a case series. Crit Care 24(1):392</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32620147</ArticleId>
            <ArticleId IdType="pmc">7332736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dwarakanath BS, Jain V (2009) Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol 5:581–585</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19519197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eweas AF, Alhossary AA, Abdel-Moneim AS (2021) Molecular docking reveals Ivermectin and Remdesivir as potential repurposed drugs against SARS-CoV-2. Front Microbiol 11:592908</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33746908</ArticleId>
            <ArticleId IdType="pmc">7976659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontaine KA, Sanchez EL, Camarda R et al (2015) Dengue virus induces and requires glycolysis for optimal replication. J Virol 89:2358–2366</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25505078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forrestall KL, Burley DE, Cash MK et al (2021) 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease. Chem Biol Interact 335:109348</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33278462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furuta Y, Gowen BB, Takahashi K et al (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivirus Res 100:446–454</Citation>
        </Reference>
        <Reference>
          <Citation>Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B 93:449–463</Citation>
        </Reference>
        <Reference>
          <Citation>Gao H, Liang D, Li C et al (2020) 2-Deoxy-Rh2: a novel ginsenoside derivative, as dual-targeting anti-cancer agent via regulating apoptosis and glycolysis. Biomed Pharmacother 124:109891</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31991384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girum T, Lentiro K, Geremew M et al (2020) Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic review. Trop Med Health 48:91</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33292755</ArticleId>
            <ArticleId IdType="pmc">7680824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halder S, Mehta AK (2021) 2-Deoxy-D-glucose: is this the final cure for COVID-19: or yet another mirage? Eur Rev Med Pharmacol Sci 25:4448–4450</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34286486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Cheng A, Kumar R et al (2020) Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J Med Virol 92:2152–2158</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32406952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Icard P, Lincet H, Wu Z et al (2021) The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. Biochimie 180:169–177</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33189832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imran M, Arora MK, Asdaq SMB et al (2021) Discovery, development, and patent trends on Molnupiravir: a prospective oral treatment for COVID-19. Molecules 26:5795</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34641339</ArticleId>
            <ArticleId IdType="pmc">8510125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivashchenko AA, Dmitriev KA, Vostokova NV et al (2020) AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis 73:531–534</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">7454388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang WD, Jeon S, Kim S et al (2021) Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. PNAS 118:e2024302118</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34234012</ArticleId>
            <ArticleId IdType="pmc">8325362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang J-H, Kim Y-J, Yang M-S et al (2021) Co-Spray dried Nafamostat mesylate with lecithin and mannitol as respirable microparticles for targeted pulmonary delivery: pharmacokinetics and lung distribution in rats. Pharmaceutics 13:1519</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34575594</ArticleId>
            <ArticleId IdType="pmc">8468663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan SA, Al-Balushi K (2021) Combating COVID-19: the role of drug repurposing and medicinal plants. J Infect Public Health 14:495–503</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33743371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kheir M, Saleem F, Wang C et al (2021) Higher albumin levels on admission predict better prognosis in patients with confirmed COVID-19. PLoS ONE 16:e0248358</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33725003</ArticleId>
            <ArticleId IdType="pmc">7963065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J-Y, You Z, Wang Q et al (2020) The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect 22:80–85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32087334</ArticleId>
            <ArticleId IdType="pmc">7079563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malin JJ, Suárez I, Priesner V et al (2021) Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev 34:e00162-e220</Citation>
        </Reference>
        <Reference>
          <Citation>Malone B, Campbell EA (2021) Molnupiravir: coding for catastrophe. Nat Struct Mol Biol 28:706–711</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34518697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantha MK, Suvvari TK, Corriero AC (2021) 2-Deoxy-D-glucose as an armament against COVID-19: the key to return to normality? Biomed Biotechnol Res J 5:347–348</Citation>
        </Reference>
        <Reference>
          <Citation>Mengist HM, Dilnessa T, Jin T (2021) Structural basis of potential inhibitors targeting SARS-CoV-2 main protease. Front Chem 9:622898</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33889562</ArticleId>
            <ArticleId IdType="pmc">8056153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merali Z, Ross S, Paré G (2014) The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metab Drug Interact 29:143–151</Citation>
        </Reference>
        <Reference>
          <Citation>Ng YL, Salim CK, Chu JJH (2021) Drug repurposing for COVID-19: approaches, challenges and promising candidates. Pharmacol Ther 228:107930</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34174275</ArticleId>
            <ArticleId IdType="pmc">8220862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicola M, Alsafi Z, Sohrabi C et al (2020) The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg 78:185–193</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32305533</ArticleId>
            <ArticleId IdType="pmc">7162753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padmanabhan S (2021) Potassium levels in COVID subjects: current observations and new possibilities for its use in COVID diagnosis. Glob J Med Res 21:1–8</Citation>
        </Reference>
        <Reference>
          <Citation>Painter GR, Bowen RA, Bluemling GR et al (2019) The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus Infection. Antiviral Res 171:104597</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31494195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter WP, HolmanW BJA et al (2021) Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother 65:e02428-e2520</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">8092915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palghadmal SB, Kulkarni PS, Makadia V et al (2021) Tackling complications of coronavirus infection with quercetin: observations and hypotheses. Explor Res Hypothesis Med 6:193–204</Citation>
        </Reference>
        <Reference>
          <Citation>Pantsar T, Poso A (2018) Binding affinity via docking: fact and fiction. Molecules 23:1899</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">6222344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul SS, Biswas G (2021) Repurposed antiviral drugs for the treatment of COVID-19: syntheses, mechanism of infection and clinical trials. Mini Rev Med Chem 21:1123–1143</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33355053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phuangsawai O, Hannongbua S, Gleeson MP (2014) Elucidating the origin of the esterase activity of human serum albumin using QM/MM calculations. J Phys Chem B 118:11886–11894</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25222879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prajapati P, Desai H, Chandarana C (2022) Hand sanitizers as a preventive measure in COVID-19 pandemic, its characteristics, and harmful effects: a review. J Egypt Public Health Assoc 97:6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35133535</ArticleId>
            <ArticleId IdType="pmc">8823197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian Y, Markowitz JS (2020) Natural products as modulators of CES1 activity. Drug Metab Dispos 48:993–1007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32591414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabie AM (2021) Discovery of (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug. Chem Pap 75:4669–4685</Citation>
        </Reference>
        <Reference>
          <Citation>Rafi MdO, Bhattacharje G, Al-Khafaji K et al (2020) Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19. J Biomol Struct Dyn 2020:1–20</Citation>
        </Reference>
        <Reference>
          <Citation>Ramière C, Rodriguez J, Enache LS et al (2014) Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A. J Virol 88:3246–3254</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24390321</ArticleId>
            <ArticleId IdType="pmc">3957934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reading PC, Allison J, Crouch EC et al (1998) Increased susceptibility of diabetic mice to Influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose? J Virol 72:6884–6887</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9658139</ArticleId>
            <ArticleId IdType="pmc">109899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rinkevich FD, Margotta JW, Simone-Finstrom M et al (2018) Esterase activity is affected by genetics, age, insecticide exposure, and viral infection in the honey bee, Apis mellifera. Biorxiv</Citation>
        </Reference>
        <Reference>
          <Citation>Sagawa T, Inoue KI, Takano H (2020) Use of protease inhibitors for the prevention of COVID-19. Prev Med 141:106280</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33035549</ArticleId>
            <ArticleId IdType="pmc">7537597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahu KK, Kumar R (2021) Role of 2-Deoxy-D-Glucose (2-DG) in COVID-19 disease: a potential game-changer. J Fam Med Prim Care 10(10):3548–3552</Citation>
        </Reference>
        <Reference>
          <Citation>Saha S, Nandi R, Vishwakarma P et al (2021) Discovering potential RNA dependent RNA polymerase inhibitors as prospective drugs against COVID-19: an in silico approach. Front Pharmacol 12:634047</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33716752</ArticleId>
            <ArticleId IdType="pmc">7952625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders JM, Monogue ML, Jodlowski TZ et al (2020) Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19). A review. JAMA 323:1824–1836</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32282022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scholtissek C, Rott R, Hau G et al (1974) Inhibition of the multiplication of vesicular stomatitis and Newcastle disease virus by 2-deoxy-D-glucose. J Virol 13:1186–1193</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4364895</ArticleId>
            <ArticleId IdType="pmc">355437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seth S, Batra J, Srinivasan S (2020) COVID-19: Targeting proteases in viral invasion and host immune response. Front Mol Biosci 7:215</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33195400</ArticleId>
            <ArticleId IdType="pmc">7581869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shang Y, Li H, Zhang R (2021a) Effects of pandemic outbreak on economies: evidence from business history context. Front Public Health 9:632043</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33777885</ArticleId>
            <ArticleId IdType="pmc">7994505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shang C, Zhuang X, Zhang H et al (2021b) Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology J 18:46</Citation>
        </Reference>
        <Reference>
          <Citation>Shen T, Wang T (2021) Metabolic reprogramming in COVID-19. Int J Mol Sci 22:11475</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34768906</ArticleId>
            <ArticleId IdType="pmc">8584248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Y, Eades W, Yan B (2021) The COVID-19 medicine Remdesivir is therapeutically activated by carboxylesterase-1, and excessive hydrolysis increases cytotoxicity. Hepatol Commun 5:1622–1623</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34510834</ArticleId>
            <ArticleId IdType="pmc">8250894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su H-X, Yao S, Zhao, W-F et al (2020) Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 1–11</Citation>
        </Reference>
        <Reference>
          <Citation>Takashita E, Kinoshita N, Yamayoshi S et al (2022) Efficacy of antibodies and antiviral drugs against COVID-19 omicron variant. N Engl J Med 386:10</Citation>
        </Reference>
        <Reference>
          <Citation>Tempestilli M, Caputi P, Avataneo V et al (2020) Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 75:2977–2980</Citation>
        </Reference>
        <Reference>
          <Citation>Teralı K, Baddal B, Gülcan HO (2020) Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment. J Mol Graph Model 100:107697</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32739642</ArticleId>
            <ArticleId IdType="pmc">7377801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vangeel L, Chiu W, De Jonghe S et al (2022) Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antivirus Res 198:105252</Citation>
        </Reference>
        <Reference>
          <Citation>Venkatesan P (2021) Repurposing drugs for treatment of COVID-19. Lancet Respir Med 9:E63</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34090608</ArticleId>
            <ArticleId IdType="pmc">8175045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl A, Gralinski LE, Johnson CE et al (2021) SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591:451–457</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33561864</ArticleId>
            <ArticleId IdType="pmc">7979515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wanat K (2020) Biological barriers, and the influence of protein binding on the passage of drugs across them. Mol Biol Rep 47:3221–3231</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32140957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhang D, Du G et al (2020) Remdesivir in adults with severe COVID-19: a randomized, double blind, placebo-controlled, multicenter trial. Lancet 395:1569–1578</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32423584</ArticleId>
            <ArticleId IdType="pmc">7190303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Li P, Solanki K et al (2021) Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Virology 564:33–38</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34619630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan VC, Muller FL (2020) Advantages of the parent nucleoside GS-441524 over Remdesivir for COVID-19 treatment. ACS Med Chem Lett 11:1361–1366</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32665809</ArticleId>
            <ArticleId IdType="pmc">7315846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Guo SS, Yi D et al (2021) A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Res 190:105078</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33894278</ArticleId>
            <ArticleId IdType="pmc">8059291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhirnov OP, Chernyshova AI (2021) Favipiravir: the hidden threat of mutagenic action. J Microbiol Epidemiol Immunobiol 98:213–220</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
